Last reviewed · How we verify
Ambrisentan plus Spironolactone
Ambrisentan blocks endothelin-1 receptors to reduce pulmonary vascular resistance, while spironolactone is a mineralocorticoid receptor antagonist that provides additional hemodynamic and anti-fibrotic benefits.
Ambrisentan blocks endothelin-1 receptors to reduce pulmonary vascular resistance, while spironolactone is a mineralocorticoid receptor antagonist that provides additional hemodynamic and anti-fibrotic benefits. Used for Pulmonary arterial hypertension (PAH).
At a glance
| Generic name | Ambrisentan plus Spironolactone |
|---|---|
| Also known as | Letairis plus Aldactone |
| Sponsor | Brigham and Women's Hospital |
| Drug class | Endothelin receptor antagonist + Mineralocorticoid receptor antagonist combination |
| Target | Endothelin-1 receptor (ETA/ETB) + Mineralocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ambrisentan is an endothelin receptor antagonist (ERA) that selectively blocks endothelin-1 signaling in pulmonary vasculature, causing vasodilation and reducing right ventricular afterload. Spironolactone, a potassium-sparing diuretic and aldosterone antagonist, reduces fluid retention and provides cardioprotective effects through mineralocorticoid receptor antagonism. The combination targets complementary pathways in pulmonary hypertension pathophysiology.
Approved indications
- Pulmonary arterial hypertension (PAH)
Common side effects
- Peripheral edema
- Headache
- Hyperkalemia
- Anemia
- Nasal congestion
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ambrisentan plus Spironolactone CI brief — competitive landscape report
- Ambrisentan plus Spironolactone updates RSS · CI watch RSS
- Brigham and Women's Hospital portfolio CI